Isomer Partners’s Cellebrite CLBT Stock Holding History

Isomer Partners’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-65,000	Closed	-$777K	–	15
2024 Q2	$777K	Sell	65,000 -555,000	-90%	-$6.2M	0.57%	16
2024 Q1	$6.87M	Sell	620,000 -600,000	-49%	-$6.12M	4.77%	8
2023 Q4	$10.6M	Sell	1,220,000 -430,000	-26%	-$3.34M	4.77%	9
2023 Q3	$12.6M	Sell	1,650,000 -535,000	-24%	-$4.02M	6.55%	9
2023 Q2	$15.7M	Sell	2,185,000 -440,000	-17%	-$2.57M	7.89%	6
2023 Q1	$16M	Sell	2,625,000 -335,000	-11%	-$1.82M	7.59%	5
2022 Q4	$12.9M	Sell	2,960,000 -115,000	-4%	-$514K	8.24%	6
2022 Q3	$12.1M	Hold	3,075,000	–	–	7.62%	6
2022 Q2	$15.7M	Hold	3,075,000	–	–	8.62%	7
2022 Q1	$19.7M	Sell	3,075,000 -215,000	-7%	-$1.43M	8.13%	6
2021 Q4	$26.4M	Sell	3,290,000 -710,000	-18%	-$6.69M	8.64%	4
2021 Q3	$37M	Buy	+4,000,000	New	+$41.8M	10.05%	3

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Crosslink Capital Menlo Park, California $1.02B AUM 9.21% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Isomer Partners's CLBT Position: Q3 2024 in Review

Isomer Partners sold out of Cellebrite (CLBT) in Q3 2024, closing a stake of 65,000 shares — an estimated $777K sold.

Isomer Partners first reported a position in CLBT in Q3 2021 and held it in 12 quarters. The position peaked at $37M in Q3 2021. 164 funds tracked by Wall St. Rank hold CLBT as of Q3 2024.

Isomer Partners reported no remaining Cellebrite position as of Q3 2024 after selling out during the quarter.
Isomer Partners sold 65,000 Cellebrite shares in Q3 2024, an estimated $777K.
Isomer Partners first reported a position in Cellebrite in Q3 2021 and held it in 12 quarters.
Isomer Partners's Cellebrite position peaked at $37M in Q3 2021.
164 funds tracked by Wall St. Rank held Cellebrite as of Q3 2024.

Based on Isomer Partners's 13F filing for Q3 2024, filed 13 Nov 2024.